CRTAC1 and chronic obstructive pulmonary disease: We now report molar concentrations of CRTAC1 as determined by an enzyme‐linked immunoassay (ELISA) in healthy normal controls and patients hospitalized with respiratory failure due to severe COVID‐19 or other causes, recovered from COVID‐19, or with chronic pulmonary disease (COPD).